Science Explorer Back to mapMap
Discussion
Topic · Hematology

Hemophilia Treatment and Research

Hemophilia Treatment and Research is a research topic within Hematology. Science Explorer counts 19k research works in it since 1950. 10.2% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the management and treatment of hemophilia, including prophylaxis, inhibitors, gene therapy, and the impact on joint health. It covers a wide range of topics such as recombinant factor VIII, factor IX, and the safety and efficacy of various treatment strategies.

  • Hemophilia
  • Factor VIII
  • Prophylaxis
  • Inhibitors
  • Recombinant Factor VIIa
  • Gene Therapy
  • Joint Disease
  • Coagulation Disorders
  • Efficacy
  • Safety
Research works
19k
fractional, since 1950
In the world top 10%
2k
per year above
Top-10% rate
10.2%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+19%
the tick is no change
Largest producer
United States
34% of the 10 largest, 2022-now
Hemophilia Treatment and Research

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Hemophilia Treatment and Research research?

By volume, the United States and China publish the most (794 and 282 works in 2022-now).

By volume, 2022-now

  1. 1 United States 794 works
  2. 2 China 282 works
  3. 3 Germany 182 works
  4. 4 India 175 works
  5. 5 United Kingdom 169 works
  6. 6 Japan 168 works
  7. 7 Italy 164 works
  8. 8 Brazil 153 works
  9. 9 France 141 works
  10. 10 Spain 129 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 33.7%China: 12.0%Germany: 7.7%India: 7.4%6 others listed: 39.2%34%largest
United States794 · 33.7%China282 · 12.0%Germany182 · 7.7%India175 · 7.4%6 others listed924 · 39.2%

Shares of the rows listed above, not of the whole node.

Which institutions lead Hemophilia Treatment and Research research?

By volume in 2022-now, University of Bonn publishes the most Hemophilia Treatment and Research research, followed by University of North Carolina at Chapel Hill and Chinese Academy of Medical Sciences & Peking Union Medical College.

By volume, 2022-now

  1. 1 University of BonnGermany 27 works
  2. 2 University of North Carolina at Chapel HillUnited States 24 works
  3. 3 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 24 works
  4. 4 Nara Medical UniversityJapan 23 works
  5. 5 Emory UniversityUnited States 23 works
  6. 6 Goethe University FrankfurtGermany 22 works
  7. 7 Hospital Universitario La PazSpain 21 works
  8. 8 Takeda (Japan)Japan 21 works
  9. 9 Capital Medical UniversityChina 21 works
  10. 10 Fondazione IRCCS Ca' Granda Ospedale Maggiore PoliclinicoItaly 21 works

Who are the leading researchers in Hemophilia Treatment and Research?

The most-cited researchers publishing on Hemophilia Treatment and Research include Giuseppe Remuzzi, Mika Kivimäki and Gregory Y.H. Lip.

  1. 1 Giuseppe Remuzzi Italy 328k citations
  2. 2 Mika Kivimäki United Kingdom 318k citations
  3. 3 Gregory Y.H. Lip United Kingdom 311k citations
  4. 4 Richard A. Gibbs United States 292k citations
  5. 5 Jean‐Louis Vincent Belgium 262k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Hemophilia Treatment and Research?

The most cited paper in Hemophilia Treatment and Research is "Mutation in blood coagulation factor V associated with resistance to activated protein C" (Rogier M. Bertina, Bobby P. C. Koeleman, Ted Koster et al., 1994), with 3,854 citations. Next come "Hematological Problems in Pediatric Intensive Care" (3,516) and "WFH Guidelines for the Management of Hemophilia, 3rd edition" (2,029).

Most cited papers
#PaperReleasedCitations
1 Mutation in blood coagulation factor V associated with resistance to activated protein C Rogier M. Bertina, Bobby P. C. Koeleman, Ted Koster et al. · Nature May 1994 3,854
2 Hematological Problems in Pediatric Intensive Care Shoshana Revel‐Vilk, Peter N. Cox, Nancy Robitaille et al. · Pediatric and adolescent medicine Book chapter 28 Nov 2013 3,516
3 WFH Guidelines for the Management of Hemophilia, 3rd edition Alok Srivastava, Elena Santagostino, Alison Dougall et al. · Haemophilia Open access Aug 2020 2,029
4 Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Björn Dahlbäck, Martin Carlsson, Peter J. Svensson · Proceedings of the National Academy of Sciences Open access Feb 1993 1,990
5 Guidelines for the management of hemophilia Alok Srivastava, A. Brewer, Evelien P. Mauser‐Bunschoten et al. · Haemophilia Open access 6 Jul 2012 1,938
All 99 most cited papers, with filters and sorting

Where is Hemophilia Treatment and Research research done?

The largest centres of Hemophilia Treatment and Research research in 2022-now are London (United Kingdom), Beijing (China), Paris (France) and Madrid (Spain). Among places with at least 20 works in it, it is an unusually large share of all research in Kashihara-shi, Bonn and Hamilton.

Largest cities, 2022-now

  1. 1 LondonUnited Kingdom 64 works
  2. 2 BeijingChina 58 works
  3. 3 ParisFrance 51 works
  4. 4 MadridSpain 49 works
  5. 5 MilanItaly 46 works
  6. 6 New YorkUnited States 41 works
  7. 7 TokyoJapan 40 works
  8. 8 Belo HorizonteBrazil 34 works
  9. 9 AtlantaUnited States 29 works
  10. 10 AmsterdamNetherlands 28 works

Where it is the local speciality

  1. Kashihara-shiJP · 21.7 works98×
  2. BonnDE · 27.0 works10×
  3. HamiltonCA · 21.1 works10×
  4. Frankfurt am MainDE · 24.6 works8.7×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Hemophilia Treatment and Research than the world average.

See Hemophilia Treatment and Research on the map

Where is the best place to study Hemophilia Treatment and Research?

Among universities, judged by research, University of Milan, Utrecht University and McMaster University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 19.95%fractional works in this field (log) →share of work in the world top 10% →University of MilanUtrecht UniversityMcMaster UniversityUniversity of Bonn
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1University of MilanItaly 75.122.3%8.3×16 +36.3%
2Utrecht UniversityNetherlands 74.321.6%7.6×17 +2.9%
3McMaster UniversityCanada 73.218.6%10.0×18 +19.0%
4University of BonnGermany 71.412.2%19.1×27 +62.9%
5Goethe University FrankfurtGermany 71.218.4%16.1×22 +70.2%
6Medical University of ViennaAustria 70.822.5%13.2×13 +47.3%
7Radboud University NijmegenNetherlands 70.531.6%5.0×9 +106.7%
8Erasmus University RotterdamNetherlands 68.121.4%6.8×11 +16.3%
9University College LondonUnited Kingdom 64.520.3%3.9×19 -19.0%
10Emory UniversityUnited States 64.110.6%9.3×23 +11.4%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Hemophilia Treatment and Research, country by country

Is Hemophilia Treatment and Research research growing?

Output in 2022-2025 was 19% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Hemophilia Treatment and Research.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Hemophilia Treatment and Research as a percentage of every work published that year, 0.014% in 2024.

still counting0.020%0.040%0.060%Hemophilia Treatment and Research0.015% in 202519801990200020102020

Fractional works of Hemophilia Treatment and Research over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Hemophilia Treatment and Research10.0% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Hemophilia Treatment and Research. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.